Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy
Shimako Yamamoto, … , Stephen F. Vatner, Junichi Sadoshima
Shimako Yamamoto, … , Stephen F. Vatner, Junichi Sadoshima
Published May 15, 2003
Citation Information: J Clin Invest. 2003;111(10):1463-1474. https://doi.org/10.1172/JCI17459.
View: Text | PDF
Article Cardiology

Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy

  • Text
  • PDF
Abstract

Activation of mammalian sterile 20–like kinase 1 (Mst1) by genotoxic compounds is known to stimulate apoptosis in some cell types. The importance of Mst1 in cell death caused by clinically relevant pathologic stimuli is unknown, however. In this study, we show that Mst1 is a prominent myelin basic protein kinase activated by proapoptotic stimuli in cardiac myocytes and that Mst1 causes cardiac myocyte apoptosis in vitro in a kinase activity–dependent manner. In vivo, cardiac-specific overexpression of Mst1 in transgenic mice results in activation of caspases, increased apoptosis, and dilated cardiomyopathy. Surprisingly, however, Mst1 prevents compensatory cardiac myocyte elongation or hypertrophy despite increased wall stress, thereby obscuring the use of the Frank-Starling mechanism, a fundamental mechanism by which the heart maintains cardiac output in response to increased mechanical load at the single myocyte level. Furthermore, Mst1 is activated by ischemia/reperfusion in the mouse heart in vivo. Suppression of endogenous Mst1 by cardiac-specific overexpression of dominant-negative Mst1 in transgenic mice prevents myocyte death by pathologic insults. These results show that Mst1 works as both an essential initiator of apoptosis and an inhibitor of hypertrophy in cardiac myocytes, resulting in a previously unrecognized form of cardiomyopathy.

Authors

Shimako Yamamoto, Guiping Yang, Daniela Zablocki, Jing Liu, Chull Hong, Song-Jung Kim, Sandra Soler, Mari Odashima, Jill Thaisz, Ghassan Yehia, Carlos A. Molina, Atsuko Yatani, Dorothy E. Vatner, Stephen F. Vatner, Junichi Sadoshima

×

Figure 8

Options: View larger image (or click on image) Download as PowerPoint
(a) Immunoblot analyses of heart homogenates with anti-myc Ab (upper pan...
(a) Immunoblot analyses of heart homogenates with anti-myc Ab (upper panel) and anti-Mst1 Ab (lower panel). (b–f) Tg-DN-Mst1 or NTg control mice were subjected to 20 min ischemia and 24 h of reperfusion or sham operation. (b) The heart homogenates (100 μg) obtained from ischemic (I) and nonischemic (N) areas of the LV of the mice received I/R, or from intact LV of the sham-operated mice were subjected to in-gel MBP kinase assays. I/R increased kinase activities of full-length Mst1 in the ischemic area of NTg mice, while activation of Mst1 by I/R was completely abolished in Tg-DN-Mst1. A faint band seen just above 61 kDa Mst1 most likely represents Mst2, a homologue of Mst1, whose activities are also abolished in the presence of DN-Mst1. n = 3. (c) LV tissue sections were subjected to TUNEL staining and DAPI staining. (d) TUNEL-positive myocytes in the ischemic area. The number of TUNEL-positive myocytes was expressed as percentage of total nuclei determined by DAPI staining. n = 5. (e) Genomic DNA was isolated from nonischemic (N) and ischemic (I) areas, and DNA-laddering assays were performed. The extent of DNA laddering in response to I/R was significantly smaller in Tg-DN-Mst1 compared with that in NTg. n = 3. (f) The effect of I/R upon the extent of LV myocardial infarction in Tg-DN-Mst1 and NTg. The myocardial infarction area/AAR (% infarct size/AAR) was determined as described in Methods. Note that % infarct size/AAR was significantly smaller in Tg-DN-Mst1 than in NTg.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts